Thus, screening programs are used for cancer detection in patients at risk for tumor development and usually include ultrasound (US) with or without serum biomarkers, such as alpha-fetoprotein (AFP) (Galle et al., 2018; Heimbach et al., 2018). Here, AFP is linked to neoplasm.